Axim Biotech

80 articles about Axim Biotech

• AXIM® Biotechnologies CEO Issues Letter to Shareholders; Reminds of Conference Call

  1/11/2023

  AXIM Biotechnologies, Inc. announced that it has issued the following letter to its shareholders providing commentary on recent milestones achieved on its commercialized diagnostic solution platform and upcoming plans and goals for the new year and beyond.

• AXIM Biotechnologies Commercial Partner Verséa Ophthalmics Highlights Benefits of AXIM’s Eye Diagnostic Solutions

  12/6/2022

  AXIM Biotechnologies, Inc, an international healthcare diagnostic solutions development company, announced that its ophthalmic diagnostic tear based solutions were featured in leading scientific media environments including Eyes On 2023 and Ophthalmology Times.

• AXIM® Biotechnologies Point-of-Care Diagnostic Test Platform Sales Commence With Verséa Ophthalmics’ Commercial Launch at AAO 2022

  9/29/2022

  AXIM Biotechnologies, Inc. announced that it has started selling its ophthalmic point-of-care diagnostic product portfolio in advance of the American Academy of Ophthalmology Annual Meeting through its exclusive commercialization partner Verséa Ophthalmics, LLC, a subsidiary of Verséa Holdings, Inc., one of the fastest growing healthcare companies in the U.S.

• AXIM Biotechnologies Celebrates Feature on the Vision is More Than 20/20™ Podcast

  7/21/2022

  AXIM Biotechnologies, Inc. announced today that its CEO John Huemoeller has been featured on the Vision is More Than 20/20™ podcast.

• AXIM Biotechnologies’ Development of Rapid Test for COVID-19 Neutralizing Antibodies is Cited to Demonstrate over 90% Sensitivity and 100% Specificity

  11/9/2021

  AXIM Biotechnologies, Inc, an international healthcare solutions company targeting COVID-19 diagnostics and oncological research, announced their publication in the Journal of Clinical Virology describing the development of a rapid test to measure levels of neutralizing antibodies to SARS-CoV-2.

• AXIM Biotechnologies Appoints Dry Eye Disease Expert and Accomplished Optometrist Dr. Kelly K. Nichols to its Medical Advisory Board

  10/20/2021

  AXIM Biotechnologies, Inc. today announced it has appointed Kelly K. Nichols, O.D., M.P.H., Ph.D. to its Medical Advisory Board. Dr. Nichols joins AXIM’s three other new Advisory Board members, including doctors Henry D. Perry , Laura Periman , and Chairman Joseph Tauber .

• AXIM® Biotechnologies Appoints Leading US Ophthalmic Surgeon and Researcher Dr. Henry D. Perry to its Medical Advisory BoardDr. Perry is Third World-Class Ophthalmologist to Join the Advisory Board

  10/11/2021

  AXIM Biotechnologies, Inc. today announced it has appointed Henry D. Perry, MD to its recently established Medical Advisory Board.

• AXIM® Biotechnologies Appoints Joseph Tauber, MD, Chief Medical Officer and Chairman of its Medical Advisory Board

  9/21/2021

  AXIM Biotechnologies, Inc. today announced that it has appointed Joseph Tauber, MD as Chief Medical Officer and Chairman of its Medical Advisory Board.

• AXIM® Biotechnologies to Acquire Technology Including Two FDA-Cleared 510(k)’s for Diagnostic Testing of Dry Eye Disease

  8/3/2021

  AXIM Biotechnologies, Inc announced today that the Company has signed a Binding Term Sheet to acquire the technology for the testing of Dry Eye Disease (DED), including two FDA authorizations and approvals for the commercial sale of two ophthalmic diagnostic lab tests.

• AXIM® Biotechnologies Begins Clinical Trials on Its ImmunoPass Rapid Diagnostic Test With Vaccine Recipients

  2/3/2021

  AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today the initiation of clinical trials for ImmunoPass, the Company’s rapid point-of-care test that semi-quantitatively measures levels of neutralizing antibodies to COVID-19. As a variety of COVID-19 vaccines begin rolling out to the general public, immunity

• AXIM® Biotechnologies to Present at the 13th Annual LD Micro Main Event Investor Conference on Monday, December 14

  12/14/2020

  AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today that the Company’s CEO John W. Huemoeller II will be presenting at the 13th Annual LD Micro Main Event investor conference on Monday, December 14, 2020, at 11:00 a.m. PST/2:00 p.m. EST. During the 10-minute presentation, Huemoeller will discuss AXIM’

• AXIM® Biotechnologies Develops ELISA-Based Neutralizing Antibody Diagnostic Test for COVID-19 and Applies for Patent; Company’s Fourth COVID-19 Test-Focused Patent Application

  12/3/2020

  AXIM® Biotechnologies, Inc.  (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or the “Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today the development and patent filing for an enzyme-linked immunosorbent assay (ELISA)-based diagnostic test (the “Test”) for the detection of SARS‐CoV-2 neutralizing antibodies. This application marks AXIM’s fourth COVID-19 neutralizing antibody-focused pat

• AXIM® Biotechnologies Applauds Vaccine Producers, Highlights Need for Rapid Antibody Testing to Ensure Immunity

  11/10/2020

  AXIM ® Biotechnologies, Inc . (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, applauds the recent announcement from a major vaccine producer that it has achieved 90 percent efficacy in its COVID-19 vaccine trial. With this news, the Company highlights that its rapid diagnostic test will be vital in analyzing vaccine recipients’ immuni

• AXIM® Biotechnologies Issues Update Letter to Shareholders - Oct 28, 2020

  10/28/2020

  AXIM® Biotechnologies, Inc., an international healthcare solutions company targeting oncological and COVID-19 research, announced that it has issued a letter to its shareholders providing commentary on the Company’s recent announcements and upcoming plans.

• AXIM® Biotechnologies Receives Notice of U.S. Patent Allowance for Proprietary Compounds and Methods Targeting Tumor Metastasis Through QSOX1

  9/22/2020

  AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today that the United States Patent and Trademark Office (USPTO) has issued the Company a new Notice of Allowance for a patent (Application No. 15/748,784) on anti-neoplastic compounds and methods targeting Quiescin Sulfhydryl Oxidase 1 (QSOX1), an enzyme impor

• AXIM® Biotechnologies Signs Exclusive Licensing, Manufacturing and Distribution Agreement for High Volume Production of the COVID-19 Rapid Neutralizing Antibody Test

  8/24/2020

  AXIM® Biotechnologies, Inc. announced that the Company has signed an exclusive limited licensing, manufacturing and distribution agreement with Empowered Diagnostics LLC for high volume production of AXIM’s rapid diagnostic test measuring levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells.

• AXIM® Biotechnologies Releases Rapid NeuCovix™ Test Results Showing Strong Agreement with COVID-19-Based Neutralization Tests

  7/23/2020

  AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announces the completion of a study highlighting the performance of NeuCovix™, AXIM’s rapid test to measure levels of neutralizing anti-COVID-19 antibodies. The NeuCovix™ test was compared to a gold standard pseudovirus-based test. NeuCovix™ accurately classified serum

• AXIM® Biotechnologies Welcomes Former Secretary of Veterans Affairs Peter O'Rourke to Company’s Board of Directors

  7/21/2020

  AXIM ® Biotechnologies, Inc. (OTCQB: AXIM) ("AXIM® Biotech," "AXIM" or "the Company"), an international healthcare solutions company targeting oncological and COVID-19 research, announced today it has welcomed Former Secretary of Veterans Affairs Peter O'Rourke to the Company’s Board of Directors. O’Rourke brings more than 20 years of experience serving in senior leadership roles in the public and private sectors. He has held leadership rol

• 

  Biopharma Update on the Novel Coronavirus: July 15

  7/15/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 15, 2020.

• AXIM® Biotechnologies Unveils First–in-Class COVID-19 Rapid Diagnostic Test for Neutralizing Antibodies and Files Pre-Emergency Use Authorization with the FDA

  7/15/2020

  AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological research, today announced the development of NeuCovix TM , a rapid diagnostic test measuring levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells. Unlike currently available serological COVID-19 tests that detect an antibody respons